The Indianapolis drugmaker said dulaglutide performed as well as Victoza, a best-selling drug for Type 2 diabetics made by Denmark-based Novo Nordisk. Analysts think dulaglutide could reach annual sales of $1.5 billion.
While life sciences companies don’t rack up huge jobs numbers, their relatively high pay means that every job they create is worth two in the rest of the private sector.
The Obama administration’s delays of Obamacare’s employer mandate penalties mean it will be another year or two before hospitals see the additional revenue the law was supposed to bring them.
Eli Lilly and Co. is buying a privately held, poultry-vaccine maker based in Germany to strengthen its Elanco animal health subsidiary.
The bulk of the money, to be spent over five years, will go to a 134,000-square-foot health sciences center, which will provide training space for the university’s nursing, physical therapy and other health care students.
John Cannon, the man credited with righting the ship at WellPoint Inc., was terminated without cause this week, the company disclosed in a securities filing Friday morning.
The construction ban is at the center of an ongoing debate between the state's existing nursing homes and developers leading a wave of construction, including Zeke Turner of Mainstreet Property Group.
Even if Gov. Mike Pence and Obama’s health secretary can’t come to terms this weekend, there are ideas bouncing around the state legislature that suggest other ways Indiana could expand coverage to low-income Hoosiers.
Most Americans are avoiding the lowest-priced health plans on the Obamacare insurance exchanges, taking advantage of government subsidies to seek more protection against high treatment costs.
Shares of Eli Lilly and Co. rose as much as 3.8 percent Wednesday morning after the Indianapolis-based drugmaker revealed that an experimental drug boosted overall survival among lung cancer patients in a large trial.
Lawmakers Young and Donnelly push restoration of 40-hour definition of full-time, but critics say their bills would gut Obamacare’s employer mandate and lead to a decline in employer insurance coverage.
Rich employer benefits are not always so attractive, sick patients are not always money losers for insurers, and hospitals and doctors are now health care preventers rather than health care providers. This is the bizarre world to which Obamacare has brought us.
The latest enrollment data from the Obamacare exchanges show that three out of four Hoosiers are purchasing decent coverage—not the super high-deductible plans that concerned hospitals.
As Scott Davison steps into the shoes of OneAmerica’s retiring CEO Dayton Molendorp, who led a massive expansion of the company in recent years, he’ll be challenged to keep growing pains at a minimum.
Nearly two-thirds of the state’s nursing homes are now participating in partnerships with county-owned hospitals that effectively double their profit margins.
Fritz French and Richard DiMarchi, the former leaders of Marcadia Biotech, have teamed up to launch the diabetes drug development firm Calibrium LLC.
The Carmel-based insurance company reported profit of $106 million, up from $101.2 million in the same quarter of 2012.
The Obama administration Monday granted employers another delay in a heavily criticized requirement that medium-to-larger firms cover their workers or face fines.
Ever since World War 2, when employers started using health benefits to compete for workers, the less employees had to pay toward health insurance premiums the more attractive the benefits. But under Obamacare, this axiom will not always be true.
Venture capitalists and angel investors put a combined $31.9 million into 18 life sciences companies last year, with some of the largest amounts going to Nextremity Solutions, hc1.com and FAST BioMedical.
